Evidence map›Paper›PMID 37391429›Full record

ArticleCell death discovery2023

Nuclear transport maintenance of USP22-AR by Importin-7 promotes breast cancer progression.

Geng-Xi Cai, Wei-Yao Kong, Yuan Liu, Shu-Yi Zhong, Qing Liu, Yuan-Fei Deng, Guo-Lin Ye

Open access · goldAbstract read
In one paragraph

Article in Cell death discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Research progress of DUB enzyme in breast cancer.Clinical and experimental medicine · 2025
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Geng-Xi Cai *Department of Breast Surgery, The First People's Hospital of Foshan, 528000, Foshan, Guangdong, China.ORCID http://orcid.org/0000-0003-0575-4314
Wei-Yao Kong *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, 511436, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0001-6444-6181
Yuan Liu *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, 511436, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0002-2234-0423
Shu-Yi ZhongGuangzhou Medical University-Guangzhou Institute of Biomedicine and Health (GMU-GIBH) Joint School of Life Sciences, Guangzhou Medical University, 511436, Guangzhou, Guangdong, China.ORCID http://orcid.org/0009-0009-0711-7109
Qing LiuDepartment of Pathology, The First People's Hospital of Foshan, 528000, Foshan, Guangdong, China.
Yuan-Fei DengDepartment of Pathology, The First People's Hospital of Foshan, 528000, Foshan, Guangdong, China. fayfei_deng@126.com.ORCID http://orcid.org/0000-0002-8326-2713
Guo-Lin YeDepartment of Breast Surgery, The First People's Hospital of Foshan, 528000, Foshan, Guangdong, China. yglin@fsyyy.com.ORCID http://orcid.org/0000-0002-6922-3435
First People's Hospital of Foshan · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The translocation of biological macromolecules between cytoplasm and nucleus is of great significance to maintain various life processes in both normal and cancer cells. Disturbance of transport function likely leads to an unbalanced state between tumor suppressors and tumor-promoting factors. In this study, based on the unbiased analysis of protein expression differences with a mass spectrometer between human breast malignant tumors and benign hyperplastic tissues, we identified that Importin-7, a nuclear transport factor, is highly expressed in breast cancer (BC) and predicts poor outcomes. Further studies showed that Importin-7 promotes cell cycle progression and proliferation. Mechanistically, through co-immunoprecipitation, immunofluorescence, and nuclear-cytoplasmic protein separation experiments, we discovered that AR and USP22 can bind to Importin-7 as cargoes to promote BC progression. In addition, this study provides a rationale for a therapeutic strategy to restream the malignant progression of AR-positive BC by inhibiting the high expression state of Importin-7. Moreover, the knockdown of Importin-7 increased the responsiveness of BC cells to the AR signaling inhibitor, enzalutamide, suggesting that targeting Importin-7 may be a potential therapeutic strategy.

Identifiers

PMID37391429
PMCPMC10313651
OpenAlexW4382651705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.